TrialDiabetes, obesity & metabolism2026

Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.

Manu V Chakravarthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.